Royalty Pharma PLC (NASDAQ:RPRX)
| 43.20 Delayed Data As of Jun 24 |  +2.12 / +5.16%Today’s Change | 34.86 Today|||52-Week Range 44.75 | +8.41% Year-to-Date |
Largest transactions by value over
| Name | Type | Date | Shares traded | Share price | Transaction value | Since transaction |
|---|---|---|---|---|---|---|
New Ventures Llc /venture Capital/ Director |  Sale | 6/29/2021 | 479,800 | $41.26 | $19.8M | +5.03% |
New Ventures Llc /venture Capital/ Director | Sale | 6/28/2021 | 167,448 | $42.11 | $7.1M | +3.10% |
Riggs Rory Balfour Director | Sale | 5/20/2022 | 123,696 | $39.28 | $4.9M | +9.31% |
Reddoch James F Chief Scientific Officer & EVP | Sale | 6/08/2022 | 100,000 | $41.56 | $4.2M | +4.12% |
Lloyd George /royalty/ | Sale | 5/23/2022 | 100,000 | $40.27 | $4.0M | +7.87% |
Lloyd George /royalty/ | Sale | 11/17/2021 | 84,148 | $42.39 | $3.6M | +1.69% |
Lloyd George /royalty/ | Sale | 5/26/2022 | 86,026 | $40.21 | $3.5M | +7.97% |
Reddoch James F Chief Scientific Officer & EVP | Sale | 5/27/2022 | 75,000 | $41.08 | $3.1M | +4.68% |
Lloyd George /royalty/ | Sale | 11/16/2021 | 72,659 | $42.33 | $3.1M | +2.88% |
Reddoch James F Chief Scientific Officer & EVP | Sale | 5/19/2022 | 75,000 | $40.44 | $3.0M | +8.60% |
Page of 6